Please login to the form below

Not currently logged in
Email:
Password:

eltrombopag

This page shows the latest eltrombopag news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Promacta receives US breakthrough therapy designation

Novartis’ Promacta receives US breakthrough therapy designation

For rare blood disorder drug Promacta (eltrombopag), the status was awarded for its use in combination with standard immunosuppressive therapy for the treatment of patients with severe aplastic anaemia (SAA) as

Latest news

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP).

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    The Swiss company announced this morning that platelet-boosting drug Revolade (eltrombopag) has become the first approved drug in the EU for adults with the rare blood disorder severe aplastic anaemia

  • Novartis aims to lead immuno-oncology category Novartis aims to lead immuno-oncology category

    The recent acquisition of cancer drugs from GlaxoSmithKline - which included Votrient (pazopanib), Tafinlar (dabrafenib), Mekinist (trametinib) and Promacta (eltrombopag) - added to its portfolio of targeted cancer therapies that can be combined

  • Novartis gets FDA nod for rare blood disorder drug Novartis gets FDA nod for rare blood disorder drug

    Promacta (eltrombopag) will be a treatment option for child patients who have had an insufficient response to corticosteroids, immunoglobins or splenectomy following its approval for adults in 2008. ... ITP who have either an insufficient response to or

  • EMA recommends two AbbVie treatments for hepatitis C EMA recommends two AbbVie treatments for hepatitis C

    Over the last year, the EMA has recommended marketing authorisations for four new medicines for the treatment of HCV, including GSK's Revolade (eltrombopag) and Janssen's Olysio (simeprevir).

More from news
Approximately 6 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics